Abstract 145P
Background
Glasgow prognostic score (GPS), which is defined with serum levels of two parameters, albumin >3.5 g/dl and C-reactive protein <1.0 mg/dl (both as 0, either as 1, and neither as 2), has a prognostic significance in various malignant solid tumors. In a small-scale retrospective study, GPS was useful as a prognostic factor for chemo-naïve advanced biliary tract cancer (ABTC) patients with good performance status (PS; defined with ECOG PS 0 and 1). We evaluated whether GPS was useful in large-scale prospective study for ABTC patients with good PS.
Methods
ABTC patients with PS 0/1 and not missing laboratory data among the patients who received gemcitabine + cisplatin (GC) or GC + S-1 (GCS) in a phase III study (MITSUBA) were analyzed for factors with P < 0.2, using multivariate Cox proportional hazards model for overall survival (OS). In the exploratory analysis, OS was compared between GC and GCS according to GPS.
Results
Clinical data were collected from 230 patients (113 patients in the GC arm and 117 patients in the GCS arm) among 241 patients. The proportion of patients was 43% in GPS 0, 35% in GPS 1, and 22% in GPS 2, respectively. In the univariate and multivariate analyses, GPS was an independent prognostic factor (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.56-0.81; P < 0.001). The median OS was 18.0 months (95%CI, 15.3-20.7), 12.6 months (95%CI, 11.4-13.8), and 7.2 (95%CI, 4.4-10.0) for patients with GPS 0, GPS 1, and GPS 2, respectively. The HRs of GCS to GC were 1.00 (95%CI, 0.64-1.55; P = 0.99), 0.72 (95%CI, 0.45-1.15; P = 0.17), and 0.57 (95%CI, 0.32-1.04; P = 0.07), for patients with GPS 0, GPS 1, and GPS 2, respectively.
Conclusions
GPS was useful for chemo-naïve ABTC patients with good PS, and GCS might improve OS, especially in patients with poor prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kansai Hepato-Biliary Oncology Group.
Funding
Taiho Pharmaceutical.
Disclosure
T. Moriwaki: Speaker Bureau / Expert testimony: Taiho Pharmaceutical; Speaker Bureau / Expert testimony: Lilly. Y. Yamamoto: Speaker Bureau / Expert testimony: Taiho. T. Yamada: Advisory / Consultancy: Taiho; Speaker Bureau / Expert testimony: Lilly. A. Taketomi: Honoraria (institution), Leadership role: Taiho. K. Yoshimura: Honoraria (self): Taiho; Honoraria (self): Lilly; Honoraria (self): Nippon Kayaku. E. Hatano: Honoraria (self): Taiho; Honoraria (self), Advisory / Consultancy: Lilly. T. Ioka: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract